Revolution Medicines, Inc.
RVMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7,337 | $3,245 | $1,921 | $1,833 |
| - Cash | $543 | $696 | $161 | $108 |
| + Debt | $136 | $88 | $64 | $67 |
| Enterprise Value | $6,930 | $2,637 | $1,823 | $1,791 |
| Revenue | $0 | $12 | $35 | $29 |
| % Growth | -100% | -67.3% | 20.4% | – |
| Gross Profit | -$592 | -$400 | -$218 | -$158 |
| % Margin | – | -3,451.3% | -615.3% | -536.1% |
| EBITDA | -$589 | -$457 | -$249 | -$180 |
| % Margin | – | -3,943.7% | -702.7% | -611.6% |
| Net Income | -$600 | -$436 | -$249 | -$187 |
| % Margin | – | -3,768.3% | -703% | -636.6% |
| EPS Diluted | -3.58 | -3.86 | -3.08 | -2.47 |
| % Growth | 7.3% | -25.3% | -24.7% | – |
| Operating Cash Flow | -$557 | -$351 | -$224 | -$147 |
| Capital Expenditures | -$10 | -$8 | -$11 | -$7 |
| Free Cash Flow | -$568 | -$358 | -$235 | -$154 |